碩士 / 國立中山大學 / 海洋生物科技暨資源學系研究所 / 107 / Neuropathic pain is a syndrome which is difficult to cure, and have many complex causes include alcohol, chemotherapy, diabetes, HIV virus, autoimmune, nerve compression or ischemia, etc. In statistic, there are 7-8 percent of people has neuropathic pain. In seven world major pharmaceutical market (America, Japan, France, Germany, Italy, Spain, United Kingdom), the drugs of neuropathic pain were sold 24 billion dollars, and it will be elevated up to 36 billion dollars in 2020. But the common analgesic drug like nonsteroidal anti-inflammatory drugs (NSAIDs) has no effect. The first-line treatment, Gabapatin, has good efficiency, but it also has severe side effect. (e.g., hives; difficult breathing; swelling of your face, lips, tongue, or throat.) In that, we need to develop more drugs which is more effective and less side effect to treat neuropathic pain. In this study, we used chronic constriction injury (CCI) rat as the animal model of neuropathic pain. We use the modified marine compounds (WH4) as agent. In result, WH4 has excellent analgesic effects. Its analgesic effect is even better than that of Gabapatin.The results showed that the mechanism may be related to melatonin MT2 receptor and metabolism, and the change maybe a new way to treat neuropathic pain. We have not found apparent side effect of WH4 in rat still now, it may be a potential compound to develop a new drug in treating neuropathic pain.
| Identifer | oai:union.ndltd.org:TW/107NSYS5277004 |
| Date | January 2018 |
| Creators | Che-Wei Kuo, 郭哲維 |
| Contributors | Wen Zhi-Hong, 溫志宏 |
| Source Sets | National Digital Library of Theses and Dissertations in Taiwan |
| Language | zh-TW |
| Detected Language | English |
| Type | 學位論文 ; thesis |
| Format | 135 |
Page generated in 0.0018 seconds